The DOI matches its Crossref record; 303 of the 303 references it cites were found in a registry or an index.
Fluoxetine versus other types of pharmacotherapy for depression
Open accessAbstract
BACKGROUND: Depression is common in primary care and is associated with marked personal, social and economic morbidity, thus creating significant demands on service providers. The antidepressant fluoxetine has been studied in many randomised controlled trials (RCTs) in comparison with other conventional and unconventional antidepressants. However, these studies have produced conflicting findings.Other systematic reviews have considered selective serotonin reuptake inhibitor (SSRIs) as a group which limits the applicability of the indings for fluoxetine alone. Therefore, this review intends to provide specific and clinically useful information regarding the effects of fluoxetine for depression compared with tricyclics (TCAs), SSRIs, serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamineoxidase inhibitors (MAOIs) and newer agents, and other conventional and unconventional agents. OBJECTIVES: To assess the effects of fluoxetine in comparison with all other antidepressive agents for depression in adult individuals with unipolar major depressive disorder. SEARCH METHODS: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis Review Group Controlled Trials Register (CCDANCTR)to 11May 2012. This register includes relevant RCTs from the Cochrane Central Register of Controlled Trials (CENTRAL) (all years),MEDLINE (1950 to date), EMBASE (1974 to date) and PsycINFO (1967 to date). No language restriction was applied. Reference lists of relevant papers and previous systematic reviews were handsearched. The pharmaceutical company marketing fluoxetine and experts in this field were contacted for supplemental data. SELECTION CRITERIA: All RCTs comparing fluoxetine with any other AD (including non-conventional agents such as hypericum) for patients with unipolar major depressive disorder (regardless of the diagnostic criteria used) were included. For trials that had a cross-over design only results from the first randomisation period were considered. DATA COLLECTION AND ANALYSIS: Data were independently extracted by two review authors using a standard form. Responders to treatment were calculated on an intention-to-treat basis: dropouts were always included in this analysis. When data on dropouts were carried forward and included in the efficacy evaluation, they were analysed according to the primary studies; when dropouts were excluded from any assessment in the primary studies, they were considered as treatment failures. Scores from continuous outcomes were analysed by including patients with a final assessment or with the last observation carried forward. Tolerability data were analysed by calculating the proportion of patients who failed to complete the study due to any causes and due to side effects or inefficacy. For dichotomous data, odds ratios (ORs) were calculated with 95% confidence intervals (CI) using the random-effects model. Continuous data were analysed using standardised mean differences (SMD) with 95% CI. MAIN RESULTS: A total of 171 studies were included in the analysis (24,868 participants). The included studies were undertaken between 1984 and 2012. Studies had homogenous characteristics in terms of design, intervention and outcome measures. The assessment of quality with the risk of bias tool revealed that the great majority of them failed to report methodological details, like the method of random sequence generation, the allocation concealment and blinding. Moreover, most of the included studies were sponsored by drug companies, so the potential for overestimation of treatment effect due to sponsorship bias should be considered in interpreting the results. Fluoxetine was as effective as the TCAs when considered as a group both on a dichotomous outcome (reduction of at least 50% on the Hamilton Depression Scale) (OR 0.97, 95% CI 0.77 to 1.22, 24 RCTs, 2124 participants) and a continuous outcome (mean scores at the end of the trial or change score on depression measures) (SMD 0.03, 95% CI -0.07 to 0.14, 50 RCTs, 3393 participants). On a dichotomousoutcome, fluoxetine was less effective than dothiepin or dosulepin (OR 2.13, 95% CI 1.08 to 4.20; number needed to treat (NNT) =6, 95% CI 3 to 50, 2 RCTs, 144 participants), sertraline (OR 1.37, 95% CI 1.08 to 1.74; NNT = 13, 95% CI 7 to 58, 6 RCTs, 1188 participants), mirtazapine (OR 1.46, 95% CI 1.04 to 2.04; NNT = 12, 95% CI 6 to 134, 4 RCTs, 600 participants) and venlafaxine(OR 1.29, 95% CI 1.10 to 1.51; NNT = 11, 95% CI 8 to 16, 12 RCTs, 3387 participants). On a continuous outcome, fluoxetine was more effective than ABT-200 (SMD -1.85, 95% CI -2.25 to -1.45, 1 RCT, 141 participants) and milnacipran (SMD -0.36, 95% CI-0.63 to -0.08, 2 RCTs, 213 participants); conversely, it was less effective than venlafaxine (SMD 0.10, 95% CI 0 to 0.19, 13 RCTs,3097 participants). Fluoxetine was better tolerated than TCAs considered as a group (total dropout OR 0.79, 95% CI 0.65 to 0.96;NNT = 20, 95% CI 13 to 48, 49 RCTs, 4194 participants) and
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression
Geddes, J. R., Freemantle, N., Mason, J. M., Eccles, M., & Boynton, J. R. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001851 · Cited by 112
RetractedDiagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Research Diagnostic Criteria: Rationale and Reliability
Spitzer, R. L. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770300115013 · Cited by 6,951
Cited by
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
Self-citationCross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud, A. M., Zotti, R. J., Shehzad, Z., Gueorguieva, R., Johnson, M. K., Trivedi, M. H., Cannon, T. D., Krystal, J. H., & Corlett, P. R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00471-x · Cited by 676
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Bauer, M., Bschor, T., Pfennig, A., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., WFSBP Task Force on Unipolar Depres, Bauer, M., Bschor, T., et al. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970701227829 · Cited by 477
Hayasaka, Y., Purgato, M., Magni, L. R., Ogawa, Y., Takeshima, N., Cipriani, A., Barbui, C., Leucht, S., & Furukawa, T. A. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.03.021 · Cited by 401
Self-citationCitalopram versus other anti-depressive agents for depression
Cipriani, A., Purgato, M., Furukawa, T. A., Trespidi, C., Imperadore, G., Signoretti, A., Churchill, R., Watanabe, N., & Barbui, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006534.pub2 · Cited by 311
Self-citationSertraline versus other antidepressive agents for depression
Cipriani, A., La Ferla, T., Furukawa, T. A., Signoretti, A., Nakagawa, A., Churchill, R., McGuire, H., & Barbui, C. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006117.pub4 · Cited by 299
Self-citationNewer generation antidepressants for depressive disorders in children and adolescents
Hetrick, S. E., McKenzie, J. E., Cox, G. R., Simmons, M. B., & Merry, S. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004851.pub3 · Cited by 291
Lam, R. W., Levitt, A. J., Levitan, R. D., Michalak, E. E., Cheung, A. H., Morehouse, R., Ramasubbu, R., Yatham, L. N., & Tam, E. M. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.2235 · Cited by 275
Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?
Ioannidis, J. P. (2008) · Philosophy, Ethics, and Humanities in Medicine · doi:10.1186/1747-5341-3-14 · Cited by 253
A Review for the Pharmacological Effect of Lycopene in Central Nervous System Disorders
Chen, D., Huang, C., & Chen, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.151 · Cited by 206
Rief, W., Nestoriuc, Y., von Lilienfeld-Toal, A., Dogan, I., Schreiber, F., Hofmann, S. G., Barsky, A. J., & Avorn, J. (2009) · Drug Safety · doi:10.2165/11316580-000000000-00000 · Cited by 202
Escitalopram versus other antidepressive agents for depression
Cipriani, A., Santilli, C., Furukawa, T. A., Signoretti, A., Nakagawa, A., McGuire, H., Churchill, R., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006532.pub2 · Cited by 190
Self-citationAshman, T. A., Cantor, J. B., Gordon, W. A., Spielman, L., Flanagan, S., Ginsberg, A., Engmann, C., Egan, M., Ambrose, F., & Greenwald, B. (2009) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2008.11.005 · Cited by 149
The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review
Olivier, J. D. A., Blom, T., Arentsen, T., & Homberg, J. R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.09.013 · Cited by 131
'Third wave' cognitive and behavioural therapies versus other psychological therapies for depression
Hunot, V., Moore, T. H., Caldwell, D. M., Furukawa, T. A., Davies, P., Jones, H., Honyashiki, M., Chen, P., Lewis, G., & Churchill, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008704.pub2 · Cited by 124
Self-citationBehavioural therapies versus other psychological therapies for depression
Shinohara, K., Honyashiki, M., Imai, H., Hunot, V., Caldwell, D. M., Davies, P., Moore, T. H., Furukawa, T. A., & Churchill, R. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008696.pub2 · Cited by 129
Self-citationDuclot, F., & Kabbaj, M. (2015) · Journal of Experimental Biology · doi:10.1242/jeb.107086 · Cited by 103
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults
McCloud, T. L., Caddy, C., Jochim, J., Rendell, J. M., Diamond, P. R., Shuttleworth, C., Brett, D., Amit, B. H., McShane, R., Hamadi, L., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011611.pub2 · Cited by 102
Self-citationBehavioural activation therapy for depression in adults
Uphoff, E., Ekers, D., Robertson, L., Dawson, S., Sanger, E., South, E., Samaan, Z., Richards, D., Meader, N., & Churchill, R. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013305.pub2 · Cited by 98
Dean, R. L., Hurducas, C., Hawton, K., Spyridi, S., Cowen, P. J., Hollingsworth, S., Marquardt, T., Barnes, A., Smith, R., McShane, R., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011612.pub3 · Cited by 95
Self-citation'Third wave' cognitive and behavioural therapies versus treatment as usual for depression
Churchill, R., Moore, T. H., Furukawa, T. A., Caldwell, D. M., Davies, P., Jones, H., Shinohara, K., Imai, H., Lewis, G., & Hunot, V. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008705.pub2 · Cited by 82
Self-citationDepression comorbidity in migraine
Amoozegar, F. (2017) · International Review of Psychiatry · doi:10.1080/09540261.2017.1326882 · Cited by 73
Effect of toll-like receptor 4 on depressive-like behaviors induced by chronic social defeat stress
Zhang, K., Lin, W., Zhang, J., Zhao, Y., Wang, X., & Zhao, M. (2020) · Brain and Behavior · doi:10.1002/brb3.1525 · Cited by 50
Movsisyan, A., Melendez-Torres, G. J., & Montgomery, P. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.03.014 · Cited by 50
ARPNet: Antidepressant Response Prediction Network for Major Depressive Disorder
Chang, B., Choi, Y., Jeon, M., Lee, J., Han, K.-M., Kim, A., Ham, B.-J., & Kang, J. (2019) · Genes · doi:10.3390/genes10110907 · Cited by 35
Hunot, V., Moore, T. H., Caldwell, D., Davies, P., Jones, H., Lewis, G., & Churchill, R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008704 · Cited by 29
If You Could Only Choose Five Psychotropic Medicines: Updating the Interagency Emergency Health Kit
van Ommeren, M., Barbui, C., de Jong, K., Dua, T., Jones, L., Perez-Sales, P., Schilperoord, M., Ventevogel, P., Yasamy, M. T., & Saxena, S. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001030 · Cited by 25
Self-citation
Metadata
- Authors
- Magni, L. R., Purgato, M., Gastaldon, C., Papola, D., Furukawa, T. A., Cipriani, A., & Barbui, C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2013-07-17
- Volume
- 2013
- Issue
- 7
- Pages
- CD004185-CD004185
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1868235462
- Cited by
- 252
- References
- 303
- FWCI
- 13.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.